You can seek FDA approval to launch a generic drug before the expiration of ABILIFY's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ABILIFY's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ABILIFY:-

You can seek FDA approval to launch a generic drug before the expiration of ABILIFY MAINTENA KIT's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ABILIFY MAINTENA KIT's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ABILIFY MAINTENA KIT:-

You can seek FDA approval to launch a generic drug before the expiration of ABRAXANE's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ABRAXANE's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ABRAXANE:-

You can seek FDA approval to launch a generic drug before the expiration of ACTONEL's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ACTONEL's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ACTONEL:-

You can seek FDA approval to launch a generic drug before the expiration of ACTOPLUS MET XR's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ACTOPLUS MET XR's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ACTOPLUS MET XR:-

A supplementary protection certificate (SPC) is a type of intellectual property right granted in the European Union. It provides an extension of the term of protection for a medicinal product that has been authorized for sale in the EU, beyond the 20-year term provided by the basic patent.

The aim of SPCs is to compensate for the time taken to get regulatory approval for a new drug, and to provide an incentive for companies to invest in research and development in the field of medicinal products.

You can seek FDA approval to launch a generic drug before the expiration of AFINITOR DISPERZ's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the AFINITOR DISPERZ's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on AFINITOR DISPERZ:-

You can seek FDA approval to launch a generic drug before the expiration of AGGRASTAT's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the AGGRASTAT's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on AGGRASTAT:-

You can seek FDA approval to launch a generic drug before the expiration of ALPHAGAN P's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ALPHAGAN P's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ALPHAGAN P:-

You can seek FDA approval to launch a generic drug before the expiration of AMRIX's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the AMRIX's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on AMRIX:-

You can seek FDA approval to launch a generic drug before the expiration of AXIRON's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the AXIRON's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on AXIRON:-

You can seek FDA approval to launch a generic drug before the expiration of BANZEL's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the BANZEL's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on BANZEL:-

You can seek FDA approval to launch a generic drug before the expiration of BELVIQ's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the BELVIQ's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on BELVIQ:-

You can seek FDA approval to launch a generic drug before the expiration of BELVIQ XR's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the BELVIQ XR's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on BELVIQ XR:-

You can seek FDA approval to launch a generic drug before the expiration of BEPREVE's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the BEPREVE's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on BEPREVE:-

You can seek FDA approval to launch a generic drug before the expiration of BETHKIS's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the BETHKIS's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on BETHKIS:-

You can seek FDA approval to launch a generic drug before the expiration of BONIVA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the BONIVA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on BONIVA:-

You can seek FDA approval to launch a generic drug before the expiration of CHANTIX's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the CHANTIX's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on CHANTIX:-

You can seek FDA approval to launch a generic drug before the expiration of CLINDESSE's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the CLINDESSE's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on CLINDESSE:-

You can seek FDA approval to launch a generic drug before the expiration of COMBIGAN's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the COMBIGAN's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on COMBIGAN:-

You can seek FDA approval to launch a generic drug before the expiration of COMPLERA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the COMPLERA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on COMPLERA:-

You can seek FDA approval to launch a generic drug before the expiration of COREG CR's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the COREG CR's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on COREG CR:-

You can seek FDA approval to launch a generic drug before the expiration of CUVPOSA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the CUVPOSA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on CUVPOSA:-

You can seek FDA approval to launch a generic drug before the expiration of DALIRESP's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the DALIRESP's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on DALIRESP:-

You can seek FDA approval to launch a generic drug before the expiration of DDAVP's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the DDAVP's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on DDAVP:-

A supplementary protection certificate (SPC) is a type of intellectual property right granted in the European Union. It provides an extension of the term of protection for a medicinal product that has been authorized for sale in the EU, beyond the 20-year term provided by the basic patent.

The aim of SPCs is to compensate for the time taken to get regulatory approval for a new drug, and to provide an incentive for companies to invest in research and development in the field of medicinal products.

You can seek FDA approval to launch a generic drug before the expiration of DEXILANT's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the DEXILANT's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on DEXILANT:-

You can seek FDA approval to launch a generic drug before the expiration of DIFFERIN's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the DIFFERIN's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on DIFFERIN:-

You can seek FDA approval to launch a generic drug before the expiration of DIFICID's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the DIFICID's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on DIFICID:-